S*********e
发帖数: 127 | 1 1) High-throughput screening using patient-derived tumor xenografts to
predict clinical trial drug response.
Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, Zhang C, Schnell C,
Yang G, Zhang Y, Balbin OA, Barbe S, Cai H, Casey F, Chatterjee S, Chiang
DY, Chuai S, Cogan SM, Collins SD, Dammassa E, Ebel N, Embry M, Green J,
Kauffmann A, Kowal C, Leary RJ, Lehar J, Liang Y, Loo A, Lorenzana E, Robert
McDonald E 3rd, McLaughlin ME, Merkin J, Meyer R, Naylor TL, Patawaran M,
Reddy A, Röelli C, Ruddy DA, Salangsang F, Santacroce F, Singh AP, Tang
Y, Tinetto W, Tobler S, Velazquez R, Venkatesan K, Von Arx F, Wang HQ, Wang
Z, Wiesmann M, Wyss D, Xu F, Bitter H, Atadja P, Lees E, Hofmann F, Li E,
Keen N, Cozens R, Jensen MR, Pryer NK, Williams JA, Sellers WR.
Nat Med. 2015 Oct 19. doi: 10.1038/nm.3954. [Epub ahead of print]
2) Patient-derived tumour xenografts as models for oncology drug development.
Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ,
Messersmith WA, Eckhardt SG.
Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50. doi: 10.1038/nrclinonc.2012.61.
Review. |
